We recently found that the product of the AES gene functions as a metastasis suppressor of colorectal cancer (CRC) in both humans and mice. Expression of amino-terminal enhancer of split (AES) protein is significantly decreased in liver metastatic lesions compared with primary colon tumors. To investigate its downregulation mechanism in metastases, we searched for transcriptional regulators of AES in human CRC and found that its expression is reduced mainly by transcriptional dysregulation and, in some cases, by additional haploidization of its coding gene. The AES promoter-enhancer is in a typical CpG island, and contains a Yin-Yang transcription factor recognition sequence (YY element). In human epithelial cells of normal colon and primary tumors, transcription factor YY2, a member of the YY family, binds directly to the YY element, and stimulates expression of AES. In a transplantation mouse model of liver metastases, however, expression of Yy2 (and therefore of Aes) is downregulated. In human CRC metastases to the liver, the levels of AES protein are correlated with those of YY2. In addition, we noticed copy-number reduction for the AES coding gene in chromosome 19p13.3 in 12% (5/42) of human CRC cell lines. We excluded other mechanisms such as point or indel mutations in the coding or regulatory regions of the AES gene, CpG methylation in the AES promoter enhancer, expression of microRNAs, and chromatin histone modifications. These results indicate that Aes may belong to a novel family of metastasis suppressors with a CpG-island promoter enhancer, and it is regulated transcriptionally.
M
etastasis is responsible for most cancer deaths. (1, 2) The metastasis cascade consists of local invasion, intravasation, transport, extravasation, formation of micrometastases, and colonization. (3) Studies over the past two decades showed that approximately 20 proteins function as metastasis suppressors in various types of cancer. (4, 5) We recently identified AES as a novel metastasis suppressor in human CRC, and it is an endogenous inhibitor of Notch signaling. (6, 7) Namely, expression of Aes inhibits metastasis of CRC cells in an orthotopic transplantation model in mice, whereas Aes gene knockout causes local invasion and intravasation of tumors in intestinal adenomatosis mice. (7) (8) (9) The expression of Aes/AES protein is decreased in liver metastases as compared with primary colon tumors in both mice and humans; however, its downregulation, the key mechanism for metastasis, has not been investigated.
Several lines of evidence indicate that expression of metastasis suppressors is controlled at the transcription level. (10) For example, expression of KAI1 is transcriptionally regulated by b-catenin and p53, negatively and positively, respectively. (11, 12) While KiSS1 is stimulated by the DRIP-130-SP1 transcription complex, (13) reversion-inducing cysteine-rich protein with RECK is transcriptionally suppressed downstream of the RAS signaling. (14) In this study, we aimed to identify regulators of AES expression. Possible mechanism(s) include transcriptional suppression, point or indel mutations in the AES coding or regulatory regions of the gene, CpG methylation in the AES promoter enhancer, transcriptional pausing, selective protein degradation, expression of miRNAs, and/or chromatin histone modifications. We present here the results showing that AES is stimulated by transcription factor YY2 in the colonic epithelium, and that expression of YY2 is decreased in liver metastatic lesions of CRC. In addition, we found that the AES gene is heterozygously deleted in 12% of CRC cell lines. We have also ruled out most other conceivable mechanisms mentioned above.
Materials and Methods
Materials and methods are provided in Data S1.
Results
Transcription of AES mRNA is initiated from a CpG island promoter at multiple sites. We focused on transcriptional regulation of the AES gene because other mechanisms did not appear to affect expression of AES protein, as described later (Fig. 1,  final section) . First, we noticed that the 1st exon of the major AES mRNA is in a CpG island (86.0% GC content, 17.5 CpG and 19.4 GpC doublets/100 bp) (Fig. 2a) . To determine the transcription start sites of the AES gene, we used 5 0 RACE. The results revealed clustered AES transcription start sites producing the major (short form of the) mRNA, with multiple 5 0 -ends in human CRC cells (Fig. 2a,b) . In addition, we found another minor (long form of the) mRNA initiated from an upstream promoter. We designate here the short mRNA as AES and the long one as AES-L (Figs 2a,S1a), because the level of the short form was much higher (>15 times) than that of the long form in the colonic epithelium and in CRC cell lines (Fig. 2c) . The high level expression of AES mRNA may be attributable to the strong CpG island promoter, in contrast to the AES-L mRNA that is driven by a weaker TATA-boxlike promoter (Fig. 2b,d ). Consistently, we failed to detect AES-L protein by Western blotting of CRC cells, although forced expression of AES-L mRNA produced a corresponding protein band in 293T cells (Fig. S1b) . In addition, exogenous expression of AES-L mRNA only weakly inhibited Notch activities in RKO and HCT116 that expressed endogenous Notch receptors, whereas AES did inhibit all Notch1-4-mediated transcription significantly (Fig. 2e) . These results suggest that AES promoter and mRNA are responsible for expression of AES protein, whereas AES-L mRNA has little significance in its expression.
Yin Yang element plays essential roles in transcription of AES gene. Because multiple transcription factors cooperatively activate CpG island promoter genes, (15) we hypothesized that AES is one of these genes. To test this hypothesis, we first searched through the AES promoter enhancer sequence for regulatory elements using ENCODE, (16) Harr plot, (17) and promoter reporter assays.
By ENCODE analysis, we found DNase I hypersensitive sites in the segment of À285 to +195, suggesting its actively transcribed state (Fig. 2a) . To determine the subregions important for expression of AES, we constructed two series of luciferase reporters that carried the partial segments of the AES promoter enhancer with or without additional CMVminimal promoter (Fig. 3) . The reporters carrying the Ba to A (À230 to À22) and Bf to A fragment (À172 to À22) showed the strongest luciferase activities (Figs 3a,b,S2a), suggesting that the enhancer activity resides between Bf and A. This enhancer sequence (downloaded from the University California, Santa Cruz Genome Browser http://genome.ucsc.edu) contains some distinct elements that can bind transcription factors such as Enhancer box binding protein, YY, and SOX (Fig. S2b) . In addition, a Harr plot analysis revealed that these recognition sequences are conserved between humans and mice (Fig. 3c,e) , and that the YY element is found even in frogs, such as Xenopus tropicalis (Fig. 3d,e) . Interestingly, the Xenopus aes promoter was not associated with a CpG island, likely because of the low density of CpG islands in the species (Fig. S2b) . (18) To determine whether these transcription factor binding elements actually participate in expression of AES in vivo, we introduced inactivating mutations into three motif sequences, and carried out reporter assays (Fig. 3f) . The constructs carrying a point mutation in the YY element, either with or without additional ones in the SOX binding and/or E box elements, significantly decreased the AES promoter activity in the CRC cell lines. Taken together, these results indicate that the YY element is essential for the AES promoter activities.
Transcription factor YY2 stimulates expression of AES from AES promoter YY element. To test whether the transcription factors that can recognize the AES promoter enhancer affect transcription of AES, we next expressed them exogenously in HCT116 and RKO CRC cell lines. Consistent with the mutagenesis analysis (Fig. 3f) , YY2 that binds to the YY element increased expression of the AES reporter significantly (Fig. 4a) , (19) although no other transcription factors (TFs) for the three elements did. Furthermore, YY2 did not affect transcription from other tumor-suppressor genes, such as TP53 or SLC5A8, although it increased the transcription from AES promoter up to approximately six times that of the vector control in a dose-dependent manner (Fig. 4b) . (20) (21) (22) Deletion of the enhancer region or a point mutation in the YY element sequence reduced the YY2-dependent transcriptional activation to 18-25% of the wild-type control (Fig. 4c) . These results (42) were cotransfected with the Notch-reporter plasmid pGa981-6. Luciferase activities are shown relative to those of the control vector-transfected cells. *P < 0.01 compared with controls.
indicate that YY2 stimulates transcription from the AES promoter by binding to the YY element.
It is reported that transcription factors YY1, YY2, and reduced expression protein 1/Zinc finger protein 42 can bind to the YY element, and activate or suppress transcription from their target promoters. (23) We therefore evaluated YY1 and YY2 for the regulation of AES expression (Figs 5,6,S3). Here, we excluded reduced expression protein 1, an embryonic stem cell marker from the evaluation, because of its lack of expression in CRC cell lines. (24) To determine whether YY1 and YY2 bound differentially to the YY element of AES promoter enhancer, we next performed EMSA using recombinant YY proteins. The binding affinity of YY2 was far stronger than that of YY1 (Figs 5a,6a,S3a). As described above (Fig. 4a) , YY1 showed much fewer effects on AES promoter activity than YY2.
To test whether YY2 bound to the genomic AES promoter, we carried out ChIP-PCR using sonicated extracts of mouse CT26 and human RKO CRC cells that endogenously expressed YY2 (Fig. S4a-c) . We confirmed that each antibody for YY proteins specifically reacted to the target antigen (Fig. S3b) and that the two independent anti-YY2 antibodies successfully immunoprecipitated YY2 protein in this analysis (Fig. S3c,d,f) . As shown in Figure 5 (b), YY2 was enriched in the AES promoter region. To further study whether YY2 affected expression of the endogenous AES gene, we then determined the levels of AES mRNA in RKO and HCT116 cells in which expression of YY2 was altered (Fig. 5c,d ). Overexpression of YY2 significantly increased the level of AES mRNA by 1.7-2.3 times (Fig. 5c) . Consistently, knockdown of YY2 in HCT116 decreased the level of AES mRNA to 35-50% of the controls (Fig. 5d) . These results indicate that YY2 can bind directly to and activate the genomic AES promoter in CRC cells.
We next analyzed expression of Aes and Yy2 proteins in mouse intestine using anti-Aes and anti-Yy2 antibodies. We first confirmed that the Yy2 signal detected by immunoblotting was weakened by siRNA against Yy2 in CT26 cells (Fig. S4a,  b) and that the protein bound by anti-Yy2 antibody included Yy2-specific fragments by mass-spectrometric analysis (Fig. S4d) . A Western blot analysis revealed that Yy2 as well (Fig. 2b) . (f) Mutagenesis analysis of the putative transcription factor binding motifs in the AES enhancer promoter. Inactivating point mutations (mut) were introduced into the respective binding sites. Green bars show the relative luciferase activities calibrated to those of the basal vector (Empty). Error bars show standard deviations of triplicated samples. *P < 0.01. DE, reporter lacking upstream of the AscI (A) site (for enhancer deletion); Ba, BamHI; Bf, BfuAI; E, EcoRI; N, NotI; T, TaqI.
as Aes was expressed in various mouse organs including the brain, liver, kidney, testis, stomach, and intestines at wide levels (Fig. S4e,f) .
Using mouse colonic epithelial cell spheroids, (25) we further found that both Aes and Yy2 proteins are expressed in the mouse colonic epithelium at significant levels (Fig. S4g) . We also confirmed their expression in the normal and adenomatous colonic epithelia by immunohistochemistry, as shown in Figure 5(e,f) . Notably, the Yy2 protein was localized both in the cytoplasm and nucleus of the colonic crypt epithelia that also expressed Aes. Likewise, we confirmed upregulation of Aes by overexpression of Yy2 protein in the normal and adenomatous colonic epithelial spheroids, and another mouse CRC cell line CT38 (Fig. 5g) . Taken together, these results suggest that expression of Aes is stimulated by Yy2 in the normal colonic, adenomatous, and cancer epithelial cells of the mouse.
Yin Yang 1 stimulates expression of AES in the presence of coactivators. Electrophoretic mobility-shift assay using recombinant YY proteins showed that the binding affinity of YY2 was far stronger than that of YY1 (Figs 5a,6a,S3a) . However, YY1 protein is abundantly expressed in mammalian normal and tumor cells (Fig. S4b,e,f ) (26) and shares the common target DNA sequence motif with YY2. (23) We therefore tested whether YY1 can bind to and stimulate the AES promoter in vivo. A ChIP-PCR analysis using sonicated extracts of HCT116 and RKO CRC cells showed that YY1 was enriched in the AES promoter region (Figs 6b,S3e,f) . To further test whether the binding enhances transcription from the AES promoter, we undertook luciferase reporter assays. Although YY1 hardly affected the AES promoter by itself (Fig. 6c) , it could disturb the YY2-mediated transcription from the AES promoter (Fig. 6d) . In contrast, YY1 stimulated expression of AES in the presence of co-activators (Fig. 6e) . (27) To further analyze the role of YY1 in stimulating expression of AES in vivo, we determined the effects of knocking down YY1 expression in CRC cell lines. Knockdown of YY1 in HCT116 or RKO cells decreased the expression levels of AES mRNA to approximately 70% of that of the controls (Fig. 6f) . We also confirmed that a simultaneous knockdown of YY1 and YY2 further decreased expression of AES (Fig. S3g) . These results indicate that YY1 can enhance AES expression in the presence of co-activators.
Levels of Aes are correlated with those of YY2 in liver metastases. By microarray analysis, we previously found that expression of Aes is downregulated in liver metastases of mouse CRC cells transplanted into mouse rectal mucosa. Accordingly, we re-examined the array data and found that Yy2 mRNA level was also decreased in metastatic lesions both in the liver and lung (Fig. S3h) , which was consistent with the immunohistopathology (Fig. S3i) . A qRT-PCR analysis confirmed reduced expression of Yy2 and Aes mRNA in mouse liver metastases, compared with the primary tumors (Fig. 7a) . Furthermore, we analyzed expression of AES and YY2 proteins by immunohistopathology in human CRC lesions metastasized to the liver, and found that the levels of AES were positively correlated with those of YY2 (Figs 7b,S5a, Table 1 ; P = 1.78 9 10 -6 ). We also confirmed the positive correlation between them even in human primary CRC (Fig. S5b , Table S1 ; P = 0.0002). In addition, we found a tendency for positive correlation between YY1 and AES expression in CRC primary tumors (P = 0.077) and in their liver metastases (P = 0.002) (Tables S2,S3) . Notably, the statistical significance for YY2 (primary tumors, P = 0.0002; liver metastases, P = 1.78 9 10 -6 ) is far stronger than that for YY1 (P = 0.077 for primary tumors and P = 0.002 for liver metastases) (Tables 1,S1-S3). Taken together, these results strongly suggest that expression of AES is driven chiefly by YY2 in both human and mouse CRC lesions.
Segmental haploidization of AES-coding chromosome in CRC cells. Recently, array-based comparative genomic hybridization analyses were carried out to study the genomic landscape of CRC, and the results were compiled in public databases. We looked into them for copy number alterations in the genomic region of chromosome 19p near the telomere where AES is located (Fig. S6a,b) . Notably, we found segmental haploidization of 19p13. http://www.ncbi.nlm.nih.gov/sky/) (Fig. S6a-c) . (28) Three of these five CRC cell lines (DLD-1, SW837, and WiDr) that were haploid for the AES gene hardly expressed AES protein (Fig. S6d, right) , suggesting that losing one of the alleles was partly responsible for the extremely reduced AES levels. Expression of AES mRNA was decreased also in other CRC cell lines without copy number alterations (e.g., HCT116, HT29, and RKO) when compared with normal colonic tissues and adenoma cell line AA/C1 (Fig. S6d,e) . These results suggest that LOH contributed to the reduced expression of AES in a subset of CRC cases in addition to transcriptional repression (Fig. 1) .
Downregulation of AES is not associated with gene mutations, promoter CpG methylation, or miRNA expression. We found that the levels of AES protein and AES mRNA were reduced significantly in human CRC cell lines compared with an adenoma cell line or colonic epithelium (Fig. S6d,e) . Consistently, one can find in cancer tissue databases that AES mRNA levels are lower than in the normal colonic mucosa (Fig. S6f) . To find additional causes of AES downregulation, we searched for mutations in the AES coding and promoter regions in CRC. However, we failed to find any mutations in AES cDNA by sequencing 14 human CRC cell lines (Fig. S7a) . Likewise, we found no mutations in the AES coding sequence in The Cancer Genome Atlas database. (29) We did not find any mutations in the AES promoter region either, including in the YY element (Fig. S7a) .
Having excluded the mutational changes in the coding and promoter sequences of AES (Fig. S7a) , we tested the possibilities of AES protein destabilization, CpG methylation in the AES promoter enhancer, promoter-proximal transcriptional pausing, (30) and expression of miRNAs, all with negative data (Figs 1,S7-S10) . We evaluated the protein stability of AES using translation inhibitor cycloheximide. AES protein was as stable as the bulk of other proteins in human CRC cells (Fig. S7d) . As shown in Figure 2(a) , AES promoter enhancer is in a typical CpG island. Accordingly, we suspected possible CpG methylation in the region. However, expression of AES was unaffected by DNA demethylating reagent 5-aza-2 0 -deoxycytidine in eight CRC cell lines (Fig. S8) . Although we also assessed the possibility of epigenetic suppression by histone modification, histone deacetylase inhibitors did not increase the expression of AES in any of six human CRC cell lines (Fig. S9) . The 3 0 -UTR of the AES gene contains an miRNA recognition motif for mir-124, which is evolutionarily conserved in mammals (Fig. S7b ). Yet, no members of the mir-124 family were expressed in the CRC cell lines at any detectable levels by qPCR (Fig. S7b,c) , consistent with a previous report. (31) We also examined the possibility of promoter-proximal transcriptional pausing, (30) but it did not appear to be taking place at levels that affected AES expression significantly (Fig. S10a-c) . These results ruled out the above mechanisms commonly found in tumor-suppressor genes, and suggested that expression of AES is regulated by other mechanisms such as specific transcription factor YY2, and by copy number reduction as presented above (Fig. 1) .
Discussion
In human CpG island promoters, binding motifs are enriched for transcription factors Sp1, E2F, and ETS, (32) as well as for BoxA, CRE, and E-box binding factors. (33) In addition, the YY element is also found in CpG island promoters far more frequently than in non-CpG island regions of the genome, driving expression of, for example, mitochondrial genes. (34) Consistently, our search through the ENCODE ChIP-seq data revealed that YY1 transcription factors are preferentially bound to CpG island promoters. (16) However, information on YY2 appears to be relatively rare.
Expression of YY2 was downregulated in 49% (27/55) of liver metastasis lesions of CRC (Fig. 7b, Table 1) . We noticed two possible mechanisms: (i) in 2% of CRC cases, point or 
indel mutations were present in the YY2 coding region, which could destabilize YY2 protein (COSMIC database, http://cancer.sanger.ac.uk/cosmic); and (ii) epigenetic changes including histone modifications appeared important for transcription of the YY2 promoter (Fig. S10d) .
We recently found that AES suppresses invasion and metastasis of CRC through Notch signaling inhibition, and forms NM foci together with Rbpj transcription complex, TLE1, and HSC70. (7, 35) It is known that transcription factor YY1 is associated with NM and nucleoli. (36) It remains to be determined whether YY2 modifies the AES-TLE1-HSC70 NM foci and thereby affects Notch signaling through transcriptional induction of AES. One of the Notch target genes inhibited by AES in CRC is DAB1.
(8) DAB1 protein is phosphorylated by ABL tyrosine kinase, which activates ABL reciprocally by stimulating its autophosphorylation, causing strong activation of ABL in a manner quite localized to the sites of invasion including intravasation. One of the targets of phosphorylation by ABL is the RAC/RHO-GEF protein TRIO at its Tyr residue 2681 (pY2681), resulting in RHO activation in CRC cells. (8) Importantly, the extent of phosphorylation at TRIO Y2681 correlates with significantly poorer prognosis of patients with CRC after surgery. (8) Accordingly, these results indicate that the transcriptional activation of YY2 followed by expression of AES leads to suppression of CRC invasion and metastasis mediated by the NOTCH-DAB1-ABL-TRIO-RHO cascade.
It has been reported that mutation profiles are hardly changed between metastatic lesions and the primary tumor, and that epigenetic changes appear to be important for metastatic progression. (37) Consistently, metastasis suppressor AES had no mutations in CRC, and its positive regulator YY2 is likely to be induced by epigenetic changes (Fig. S10d) . (38) It is also possible that the copy-number reduction at the AES locus plays a role in metastatic progression in a subset of cancer cases. Namely, the chromosomal region 19p13.3 including AES is deleted often in other types of cancer such as lung cancer, lymphoma, and breast carcinoma, (39) (40) (41) although its frequency in CRC is only approximately 3% (7/280; http:// www.ncbi.nlm.nih.gov/sky/). Accordingly, it is possible that partial haploidization at 19p13.3 contributes to the progression of multiple types of cancer. Further investigations will be needed to elucidate the precise mechanisms that affect AES expression upstream of YY2.
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